FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120283294> ?p ?o ?g. }

• W3120283294 endingPage "225" @default.
• W3120283294 startingPage "211" @default.
• W3120283294 abstract "Neuroblastoma (NB) is a heterogenous disease with treatment varying from observation for low‑risk tumors, to extensive therapy with chemotherapy, surgery, radiotherapy, and autologous bone‑marrow‑transplantation and immunotherapy. However, a high frequency of primary‑chemo‑refractory disease and recurrences urgently require novel treatment strategies. The present study therefore investigated the anti‑NB efficacy of the recently FDA‑approved phosphoinositide 3‑kinase (PI3K) and fibroblast growth factor receptor (FGFR) inhibitors, alpelisib (BYL719) and erdafitinib (JNJ‑42756493), alone and in combination with or without cisplatin, vincristine, or doxorubicin on 5 NB cell lines. For this purpose, the NB cell lines, SK‑N‑AS, SK‑N‑BE(2)‑C, SK‑N‑DZ, SK‑N‑FI and SK‑N‑SH (where SK‑N‑DZ had a deletion of PIK3C2G and none had FGFR mutations according to the Cancer Program's Dependency Map, although some were chemoresistant), were tested for their sensitivity to FDA‑approved inhibitors alone or in combination, or together with cytostatic drugs by viability, cytotoxicity, apoptosis and proliferation assays. The results revealed that monotherapy with alpelisib or erdafitinib resulted in a dose‑dependent inhibition of cell viability and proliferation. Notably, the combined use of PI3K and FGFR inhibitors resulted in an enhanced efficacy, while their combined use with the canonical cytotoxic agents, cisplatin, vincristine and doxorubicin, resulted in variable synergistic, additive and antagonistic effects. Collectively, the present study provides pre‑clinical evidence that PI3K and FGFR inhibitors exhibit promising anti‑NB activity. The data presented herein also indicate that the incorporation of these inhibitors into chemotherapeutic regimens requires careful consideration and further research in order to obtain a beneficial efficacy. Nevertheless, the addition of PI3K and FGFR inhibitors to the treatment arsenal might reduce the occurrence of refractory and relapsing disease in NB without FGFR and PI3K mutations." @default.
• W3120283294 created "2021-01-18" @default.
• W3120283294 creator A5006381517 @default.
• W3120283294 creator A5021179787 @default.
• W3120283294 creator A5028584387 @default.
• W3120283294 creator A5056421344 @default.
• W3120283294 creator A5057650375 @default.
• W3120283294 creator A5077987319 @default.
• W3120283294 creator A5082808825 @default.
• W3120283294 creator A5087537729 @default.
• W3120283294 date "2021-01-05" @default.
• W3120283294 modified "2023-10-16" @default.
• W3120283294 title "Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines" @default.
• W3120283294 cites W1558704041 @default.
• W3120283294 cites W1578932543 @default.
• W3120283294 cites W1854073441 @default.
• W3120283294 cites W1864905496 @default.
• W3120283294 cites W1928010129 @default.
• W3120283294 cites W1970147400 @default.
• W3120283294 cites W1983710920 @default.
• W3120283294 cites W2006412867 @default.
• W3120283294 cites W2011340985 @default.
• W3120283294 cites W2055560819 @default.
• W3120283294 cites W2064013031 @default.
• W3120283294 cites W2085733767 @default.
• W3120283294 cites W2096439168 @default.
• W3120283294 cites W2104167441 @default.
• W3120283294 cites W2113727201 @default.
• W3120283294 cites W2124358755 @default.
• W3120283294 cites W2147063563 @default.
• W3120283294 cites W2165267819 @default.
• W3120283294 cites W2171497046 @default.
• W3120283294 cites W2178285892 @default.
• W3120283294 cites W2208494337 @default.
• W3120283294 cites W2299951717 @default.
• W3120283294 cites W2345454659 @default.
• W3120283294 cites W2402374914 @default.
• W3120283294 cites W2466354473 @default.
• W3120283294 cites W2572663347 @default.
• W3120283294 cites W2736050027 @default.
• W3120283294 cites W2752617269 @default.
• W3120283294 cites W2791843201 @default.
• W3120283294 cites W2797653167 @default.
• W3120283294 cites W2808103253 @default.
• W3120283294 cites W2921991537 @default.
• W3120283294 cites W2923057410 @default.
• W3120283294 cites W2945564879 @default.
• W3120283294 cites W2946128073 @default.
• W3120283294 cites W2979481431 @default.
• W3120283294 cites W2980125816 @default.
• W3120283294 cites W2995145967 @default.
• W3120283294 cites W2997598382 @default.
• W3120283294 cites W3217485783 @default.
• W3120283294 doi "https://doi.org/10.3892/ijo.2021.5167" @default.
• W3120283294 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7864013" @default.
• W3120283294 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33491755" @default.
• W3120283294 hasPublicationYear "2021" @default.
• W3120283294 type Work @default.
• W3120283294 sameAs 3120283294 @default.
• W3120283294 citedByCount "15" @default.
• W3120283294 countsByYear W31202832942021 @default.
• W3120283294 countsByYear W31202832942022 @default.
• W3120283294 countsByYear W31202832942023 @default.
• W3120283294 crossrefType "journal-article" @default.
• W3120283294 hasAuthorship W3120283294A5006381517 @default.
• W3120283294 hasAuthorship W3120283294A5021179787 @default.
• W3120283294 hasAuthorship W3120283294A5028584387 @default.
• W3120283294 hasAuthorship W3120283294A5056421344 @default.
• W3120283294 hasAuthorship W3120283294A5057650375 @default.
• W3120283294 hasAuthorship W3120283294A5077987319 @default.
• W3120283294 hasAuthorship W3120283294A5082808825 @default.
• W3120283294 hasAuthorship W3120283294A5087537729 @default.
• W3120283294 hasBestOaLocation W31202832941 @default.
• W3120283294 hasConcept C126322002 @default.
• W3120283294 hasConcept C143998085 @default.
• W3120283294 hasConcept C170493617 @default.
• W3120283294 hasConcept C2776694085 @default.
• W3120283294 hasConcept C2776715637 @default.
• W3120283294 hasConcept C2776755627 @default.
• W3120283294 hasConcept C2778239845 @default.
• W3120283294 hasConcept C2779429289 @default.
• W3120283294 hasConcept C2781303535 @default.
• W3120283294 hasConcept C502942594 @default.
• W3120283294 hasConcept C54355233 @default.
• W3120283294 hasConcept C71924100 @default.
• W3120283294 hasConcept C74373430 @default.
• W3120283294 hasConcept C81885089 @default.
• W3120283294 hasConcept C82867764 @default.
• W3120283294 hasConcept C86803240 @default.
• W3120283294 hasConcept C98274493 @default.
• W3120283294 hasConceptScore W3120283294C126322002 @default.
• W3120283294 hasConceptScore W3120283294C143998085 @default.
• W3120283294 hasConceptScore W3120283294C170493617 @default.
• W3120283294 hasConceptScore W3120283294C2776694085 @default.
• W3120283294 hasConceptScore W3120283294C2776715637 @default.
• W3120283294 hasConceptScore W3120283294C2776755627 @default.
• W3120283294 hasConceptScore W3120283294C2778239845 @default.
• W3120283294 hasConceptScore W3120283294C2779429289 @default.

• next